Antonella Castagna

Summary

Affiliation: San Raffaele Scientific Institute
Country: Italy

Publications

  1. ncbi request reprint Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: a randomized pilot study (E-184V study)
    Antonella Castagna
    Clinic of Infectious Diseases, Vita Salute San Raffaele University, Milan, Italy
    AIDS 20:795-803. 2006
  2. pmc Determinants of access to experimental antiretroviral drugs in an Italian cohort of patients with HIV: a multilevel analysis
    Enrico Girardi
    Department of Epidemiology and Preclinical Research, National Institute for Infectious Diseases L, Spallanzani, IRCCS, Via Portuense 292, 00149, Rome, Italy
    BMC Health Serv Res 12:38. 2012
  3. pmc Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTI
    Carlo Torti
    University of Brescia, Italy
    BMC Infect Dis 11:23. 2011
  4. ncbi request reprint Redistribution of human immunodeficiency virus type 1 variants resistant to protease inhibitors after a protease inhibitor-sparing regimen
    Nicola Gianotti
    Clinic of Infectious Diseases, Vita Salute San Raffaele University, Milan, Italy
    AIDS Res Hum Retroviruses 21:545-54. 2005
  5. ncbi request reprint Ability of different lopinavir genotypic inhibitory quotients to predict 48-week virological response in highly treatment-experienced HIV-infected patients receiving lopinavir/ritonavir
    Nicola Gianotti
    Clinic of Infectious Diseases, Universita Vita Salute San Raffaele, Milan, Italy
    J Med Virol 78:1537-41. 2006
  6. ncbi request reprint The 118I reverse transcriptase mutation is the only independent genotypic predictor of virologic failure to a stavudine-containing salvage therapy in HIV-1-infected patients
    Nicola Gianotti
    Clinic of Infectious Diseases, Vita Salute San Raffaele University, Italy
    J Acquir Immune Defic Syndr 41:447-52. 2006
  7. doi request reprint Viro-immunological dynamics in HIV-1-infected subjects receiving once-a-week emtricitabine to delay treatment change after failure: a pilot randomised trial
    Alessandro Soria
    Department of Infectious Diseases, San Raffaele Scientific Institute, Milan, Italy
    J Clin Virol 47:253-7. 2010
  8. ncbi request reprint Evaluation of atazanavir Ctrough, atazanavir genotypic inhibitory quotient, and baseline HIV genotype as predictors of a 24-week virological response in highly drug-experienced, HIV-infected patients treated with unboosted atazanavir
    Nicola Gianotti
    Clinic of Infectious Diseases, Vita Salute San Raffaele University, Milan, Italy
    New Microbiol 28:119-25. 2005
  9. ncbi request reprint Predictors of sustained response to therapy resumption after treatment interruption in HIV-infected patients failing antiretroviral therapy
    Nicola Gianotti
    Clinic of Infectious Diseases, Vita Salute San Raffaele University, Milan, Italy
    J Med Virol 72:181-6. 2004
  10. doi request reprint Predicting the magnitude of short-term CD4+ T-cell recovery in HIV-infected patients during first-line highly active antiretroviral therapy
    Antonella Castagna
    Infectious Diseases Department, San Raffaele Scientific Institute, Milan, Italy
    Antivir Ther 15:165-75. 2010

Collaborators

Detail Information

Publications45

  1. ncbi request reprint Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: a randomized pilot study (E-184V study)
    Antonella Castagna
    Clinic of Infectious Diseases, Vita Salute San Raffaele University, Milan, Italy
    AIDS 20:795-803. 2006
    ..We compared the immunological and clinical outcomes of lamivudine monotherapy and complete therapy interruption in the treatment of HIV-1-infected patients harbouring lamivudine-resistant virus...
  2. pmc Determinants of access to experimental antiretroviral drugs in an Italian cohort of patients with HIV: a multilevel analysis
    Enrico Girardi
    Department of Epidemiology and Preclinical Research, National Institute for Infectious Diseases L, Spallanzani, IRCCS, Via Portuense 292, 00149, Rome, Italy
    BMC Health Serv Res 12:38. 2012
    ..Identification of the determinants of access to investigational drugs is important to promote equity and scientific validity in clinical research. We aimed to analyze factors associated with the use of experimental antiretrovirals in Italy...
  3. pmc Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTI
    Carlo Torti
    University of Brescia, Italy
    BMC Infect Dis 11:23. 2011
    ..Data regarding CD4+ recovery after switching from protease inhibitor (PI)-based regimens to regimens not containing PI are scarce...
  4. ncbi request reprint Redistribution of human immunodeficiency virus type 1 variants resistant to protease inhibitors after a protease inhibitor-sparing regimen
    Nicola Gianotti
    Clinic of Infectious Diseases, Vita Salute San Raffaele University, Milan, Italy
    AIDS Res Hum Retroviruses 21:545-54. 2005
    ..In highly PI-experienced patients, a PI-sparing regimen may lead to a reduction, no change, or increase in the number of PI mutations. The reduction is negligible in most cases...
  5. ncbi request reprint Ability of different lopinavir genotypic inhibitory quotients to predict 48-week virological response in highly treatment-experienced HIV-infected patients receiving lopinavir/ritonavir
    Nicola Gianotti
    Clinic of Infectious Diseases, Universita Vita Salute San Raffaele, Milan, Italy
    J Med Virol 78:1537-41. 2006
    ..All of the GIQs were independent predictors of the 48-week virological response. The predictive value of the GIQ for lopinavir/ritonavir may vary depending on the algorithm used to score drug resistance...
  6. ncbi request reprint The 118I reverse transcriptase mutation is the only independent genotypic predictor of virologic failure to a stavudine-containing salvage therapy in HIV-1-infected patients
    Nicola Gianotti
    Clinic of Infectious Diseases, Vita Salute San Raffaele University, Italy
    J Acquir Immune Defic Syndr 41:447-52. 2006
    ..0001). The multivariable analysis showed that the 118I mutation (P = 0.04) was the only independent genotypic predictor of failing on a stavudine- containing highly active antiretroviral therapy...
  7. doi request reprint Viro-immunological dynamics in HIV-1-infected subjects receiving once-a-week emtricitabine to delay treatment change after failure: a pilot randomised trial
    Alessandro Soria
    Department of Infectious Diseases, San Raffaele Scientific Institute, Milan, Italy
    J Clin Virol 47:253-7. 2010
    ..In HIV-1-infected patients harbouring the M184V mutation (M184V), lamivudine monotherapy leads to a smaller decrease in CD4 percentages (CD4%) than treatment interruption, possibly due to the reduced fitness of the mutated virus...
  8. ncbi request reprint Evaluation of atazanavir Ctrough, atazanavir genotypic inhibitory quotient, and baseline HIV genotype as predictors of a 24-week virological response in highly drug-experienced, HIV-infected patients treated with unboosted atazanavir
    Nicola Gianotti
    Clinic of Infectious Diseases, Vita Salute San Raffaele University, Milan, Italy
    New Microbiol 28:119-25. 2005
    ..In conclusion, the number of ATV resistance mutations is the only correlate to virological response through 24 weeks of treatment with unboosted atazanavir 400 mg once daily...
  9. ncbi request reprint Predictors of sustained response to therapy resumption after treatment interruption in HIV-infected patients failing antiretroviral therapy
    Nicola Gianotti
    Clinic of Infectious Diseases, Vita Salute San Raffaele University, Milan, Italy
    J Med Virol 72:181-6. 2004
    ..A sustained virologic response to therapy resumption after treatment interruption can be achieved in the setting of virologic failure. An evaluation of clinical history may help to identify the patients who are more likely to respond...
  10. doi request reprint Predicting the magnitude of short-term CD4+ T-cell recovery in HIV-infected patients during first-line highly active antiretroviral therapy
    Antonella Castagna
    Infectious Diseases Department, San Raffaele Scientific Institute, Milan, Italy
    Antivir Ther 15:165-75. 2010
    ..The extent of short-term CD4(+) T-cell recovery in patients tolerating first-line highly active antiretroviral therapy (HAART) and attaining undetectable HIV RNA levels is inadequately defined...
  11. ncbi request reprint Selective increase in serum IgE following enfuvirtide administration in HIV-1 infected multidrug resistant patients
    Hamid Hasson
    San Raffaele Scientific Institute, Clinic of Infectious Diseases, Via Stamira d Ancona 20, 20127 Milan, Italy
    New Microbiol 29:223-30. 2006
    ..The immunological response associated with ENF treatment is accompanied by a selective increase in IgE levels. Determination of IgE could be used in the monitoring ISRs associated with ENE..
  12. doi request reprint Changes in darunavir/r resistance score after previous failure to tipranavir/r in HIV-1-infected multidrug-resistant patients
    Vincenzo Spagnuolo
    Department of Infectious Diseases, San Raffaele Scientific Institute, Milan, Italy
    J Acquir Immune Defic Syndr 50:192-5. 2009
    ..To evaluate changes in resistance to tipranavir/r (TPV/r) and darunavir/r (DRV/r) in patients who had failed a TPV/r-including regimen...
  13. doi request reprint Survival of HIV-1 infected multidrug-resistant patients recycling enfuvirtide after a previous failure
    Francesca Cossarini
    Department of Infectious Diseases, San Raffaele Scientific Institute, Milan, Italy
    J Acquir Immune Defic Syndr 51:179-84. 2009
    ..We evaluated long-term survival in multidrug-resistant patients recycling ENF after a previous failure...
  14. ncbi request reprint The NIQ of lopinavir is predictive of a 48-week virological response in highly treatment-experienced HIV-1-infected subjects treated with a lopinavir/ritonavir-containing regimen
    Antonella Castagna
    Clinic of Infectious Diseases, Vita Salute San Raffaele University, Milan, Italy
    Antivir Ther 9:537-43. 2004
    ..To investigate the normalized inhibitory quotient (NIQ) of lopinavir (LPV) as a predictor of 48-week virological responses to a lopinavir/ritonavir (LPV/RTV)-containing regimen in highly treatment-experienced patients...
  15. ncbi request reprint HIV-1 replication capacity and genotype changes in patients undergoing treatment interruption or lamivudine monotherapy
    Nicola Gianotti
    Divisione di Malattie Infettive, Istituto Scientifico San Raffaele, Milan, Italy
    J Med Virol 80:201-8. 2008
    ..The de-selection of the 184V mutation predicts independently a reduction in the CD4+/CD8+ ratio...
  16. ncbi request reprint Resistance to amprenavir before and after treatment with lopinavir/ritonavir in highly protease inhibitor-experienced HIV patients
    Hamid Hasson
    Clinic of Infectious Diseases, Vita Salute San Raffaele University, Milan, Italy
    AIDS 18:123-7. 2004
    ..Treatment with LPV/r can select for the 50 V mutation. In this setting, significant differences in the inference of the amprenavir phenotype from genotype were observed when using different algorithms...
  17. ncbi request reprint Switching to unboosted atazanavir improves glucose tolerance in highly pretreated HIV-1 infected subjects
    Monica Guffanti
    Clinic of Infectious Diseases, San Raffaele Scientific Institute, Via Stamira d Ancona 20, 20127 Milan, Italy
    Eur J Endocrinol 156:503-9. 2007
    ..To evaluate the 24-week effects on glucose tolerance of switching from a protease inhibitor (PI)-based to an unboosted atazanavir-including regimen in highly pretreated HIV-1 infected subjects with metabolic alterations...
  18. ncbi request reprint In vivo dynamics of the K103N mutation following the withdrawal of non-nucleoside reverse transcriptase inhibitors in Human Immunodeficiency Virus-infected patients
    Nicola Gianotti
    Clinic of Infectious Diseases, Vita Salute San Raffaele University, Milan, Italy
    New Microbiol 28:319-26. 2005
    ..This suggests that the K103N mutation per se has little impact on viral fitness in vivo...
  19. ncbi request reprint Electrocardiographic changes in HIV-infected, drug-experienced patients being treated with atazanavir
    Nicola Gianotti
    Divisione di Malattie Infettive, Istituto Scientifico San Raffaele, Milan, Italy
    AIDS 21:1648-51. 2007
    ..The electrocardiographic monitoring of patients treated with atazanavir seems advisable...
  20. doi request reprint Residual viraemia does not influence 1 year virological rebound in HIV-infected patients with HIV RNA persistently below 50 copies/mL
    Nicola Gianotti
    Department of Infectious Diseases, San Raffaele Scientific Institute, Milan, Italy
    J Antimicrob Chemother 67:213-7. 2012
    ..It is currently debated whether patients with residual viraemia are at higher risk of virological failure than those attaining <1 HIV RNA copy/mL. We therefore investigated the effect of residual viraemia on virological rebound...
  21. ncbi request reprint Impact of a treatment including tenofovir plus didanosine on the selection of the 65R mutation in highly drug-experienced HIV-infected patients
    Nicola Gianotti
    Clinic of Infectious Diseases, Vita Salute San Raffaele University, Milan, Italy
    AIDS 18:2205-8. 2004
    ..After a median of 26 weeks of treatment, two patients (10%) selected the 65R mutation. These results support the hypothesis that NEM hinder the selection of this mutation...
  22. doi request reprint Risk of type 2 diabetes among HIV-infected and healthy subjects in Italy
    Laura Galli
    Infectious Diseases, San Raffaele Scientific Institute, Milan, Italy
    Eur J Epidemiol 27:657-65. 2012
    ....
  23. ncbi request reprint Management of HIV infection after triple class failure
    Francesca Cossarini
    Department of Infectious Diseases, San Raffaele Scientific Institute, Milan, Italy
    New Microbiol 36:23-39. 2013
    ....
  24. doi request reprint Late presenters in new HIV diagnoses from an Italian cohort of HIV-infected patients: prevalence and clinical outcome
    Antonella d'Arminio Monforte
    Clinic of Infectious and Tropical Diseases, Department of Medicine, Surgery and Dentistry, S Paolo Hospital, University of Milan, Milan, Italy
    Antivir Ther 16:1103-12. 2011
    ..To study the prevalence, predictors and outcome of late HIV diagnosis in the Icona cohort, according to the new European consensus definition of late diagnosis...
  25. doi request reprint Incidence, timing, and determinants of bacterial pneumonia among HIV-infected patients: data from the ICONA Foundation Cohort
    Cristina Mussini
    Clinic of Infectious Diseases, University of Modena and Reggio Emilia, Modena, Italy
    J Acquir Immune Defic Syndr 63:339-45. 2013
    ..The aim of the study was to evaluate incidence and determinants of bacterial pneumonia (BP) after starting combination antiretroviral therapy (cART) in the Italian Cohort of Antiretroviral-Naive Patients...
  26. doi request reprint Unexpected dramatic increase in CD4+ cell count in a patient with AIDS after enfuvirtide treatment despite persistent viremia and resistance mutations
    Alessandro Soria
    Clinic of Infectious Diseases, San Raffaele Scientific Institute, Milan, Italy
    J Med Virol 80:937-41. 2008
    ..A complex interplay of viral and host factors, including the control of X4 viruses and proviral burden, may favor immune restoration with HIV neutralizing activity, despite persistent viremia...
  27. doi request reprint Immune recovery and T cell subset analysis during effective treatment with maraviroc
    Francesca Cossarini
    Department of Infectious Diseases, San Raffaele Scientific Institute, Milan, Italy
    J Antimicrob Chemother 67:2474-8. 2012
    ..Patients treated with maraviroc frequently show high CD4+ T cell increases. The aim of this study was to detail the characteristics of maraviroc-induced immune recovery...
  28. doi request reprint Cross-resistance profile of the novel integrase inhibitor Dolutegravir (S/GSK1349572) using clonal viral variants selected in patients failing raltegravir
    Filippo Canducci
    Vita Salute San Raffaele University, Laboratory of Virology and Microbiology, Milan, Italy
    J Infect Dis 204:1811-5. 2011
    ..However, viruses with mutation Q148R associated with secondary mutations and the combination Q148H+G140S were instead associated with a reduced level of susceptibility to dolutegravir in vitro...
  29. doi request reprint Clinical, virologic, and immunologic outcomes in lymphoma survivors and in cancer-free, HIV-1-infected patients: a matched cohort study
    Vincenzo Spagnuolo
    Infectious Disease Department, San Raffaele Scientific Institute, Milan, Italy
    Cancer 119:2710-9. 2013
    ....
  30. ncbi request reprint Boosted or unboosted atazanavir as a simplification of lopinavir/ritonavir-containing regimens
    Antonella Castagna
    Department of Infectious Diseases, San Raffaele Scientific Institute, Milan, Italy
    New Microbiol 36:239-49. 2013
    ..014). Replacing lopinavir/r with ATV or ATV/r yielded similar rates of virological rebound. Viral load at the initiation of lopinavir/r may be useful in driving the choice between ATV/r and ATV...
  31. doi request reprint Ten-year survival among HIV-1-infected subjects with AIDS or non-AIDS-defining malignancies
    Vincenzo Spagnuolo
    Infectious Diseases Department, San Raffaele Scientific Institute, Milan, Italy
    Int J Cancer 130:2990-6. 2012
    ..5% ± 14.5% vs. 40.0% ± 12.7%; log-rank test: p = 0.005). Despite the better cancer prognosis during the post-HAART era, the 10-year survival of HIV-infected subjects with an ADM or NADM is poor...
  32. doi request reprint Mortality of HIV-infected patients with or without cancer: comparison with the general population in Italy
    Laura Galli
    Department of Infectious Diseases, San Raffaele Scientific Institute, Milan, Italy
    Antivir Ther 17:447-58. 2012
    ..HAART has reduced mortality in HIV-infected patients; however, the risk of non-AIDS-related events has increased, including cancer. We compared mortality in HIV-infected patients with or without cancer with the general population in Italy...
  33. ncbi request reprint Pharmacokinetics of amprenavir given once or twice a day when combined with atazanavir in heavily pre-treated HIV-positive patients
    Monica Guffanti
    Department of Infectious Diseases, Vita Salute University, San Raffaele Scientific Institute, Milan, Italy
    AIDS 17:2669-71. 2003
    ..Our preliminary results suggest that amprenavir and atazanavir could be coadministered and that amprenavir could be boosted by atazanavir without the need for ritonavir pharmaco-enhancement...
  34. ncbi request reprint Long-term glucose tolerance in highly experienced HIV-infected patients receiving nucleoside analogue-sparing regimens
    Alba Bigoloni
    aDepartment of Infectious Diseases, San Raffaele Scientific Institute bUniversità Vita Salute San Raffaele cCardiometabolic and Clinical Trials Unit, Metabolic and Cardiovascular Division, Internal Medicine Department, San Raffaele Scientific Institute, Milan, Italy
    AIDS 26:1837-40. 2012
    ..A worsening glucose tolerance was observed in highly treatment-experienced HIV-infected patients receiving effective antiretroviral therapy after virological failure...
  35. doi request reprint Microbial translocation predicts disease progression of HIV-infected antiretroviral-naive patients with high CD4+ cell count
    Giulia Marchetti
    Department of Medicine, Surgery and Dentistry, Clinic of Infectious Diseases, San Paolo Hospital, University of Milan, Italy
    AIDS 25:1385-94. 2011
    ..We investigated the significance of microbial translocation measured on average 3 years after HIV seroconversion in driving disease progression in HIV untreated patients with high CD4(+) cell count...
  36. ncbi request reprint Immunological basis for IgE hyper-production in enfuvirtide-treated HIV- positive patients
    Samuele E Burastero
    Unit of Leukocyte Biology, San Raffaele Scientific Institute, Milan, Italy
    J Clin Immunol 26:168-76. 2006
    ..The hyper-IgE production in ENF-treated patients is associated with the in vitro induction of a type-2 phenotype in CD4 T cells...
  37. doi request reprint No pol mutation is associated independently with the lack of immune recovery in patients infected with HIV and failing antiretroviral therapy
    Nicola Gianotti
    Department of Infectious Diseases, IRCCS San Raffaele, Milan, Italy
    J Med Virol 83:391-8. 2011
    ..145 per 0.1-unit increase, 95% CI=1.093-1.202, P<0.0001), and with earlier calendar years of resistance testing (overall effect: P=0.0007). In conclusion, no pol mutation is associated independently with the lack of immune recovery...
  38. ncbi request reprint Magnitude and determinants of CD4 recovery after HAART resumption after 1 cycle of treatment interruption
    Cristina Mussini
    Clinic of Infectious Diseases, University of Modena and Reggio Emilia, Modena, Italy
    J Acquir Immune Defic Syndr 52:588-94. 2009
    ..The extent of immune reconstitution following HAART resumption after 1 cycle of treatment interruption (TI) is not well known...
  39. doi request reprint Viral tropism by geno2pheno as a tool for predicting CD4 decrease in HIV-1-infected naive patients with high CD4 counts
    Silvia Nozza
    San Raffaele Scientific Institute, Milan, Italy
    J Antimicrob Chemother 67:1224-7. 2012
    ..To investigate the value of tropism (determined by genotypic testing) to predict CD4 depletion in HIV-infected antiretroviral-naive patients with high CD4 counts...
  40. doi request reprint Non-invasive fibrosis biomarkers - APRI and Forns - are associated with liver stiffness in HIV-monoinfected patients receiving antiretroviral drugs
    Hamid Hasson
    Department of Infectious Diseases, IRCCS Ospedale San Raffaele, Milan, Italy
    Liver Int 33:1113-20. 2013
    ....
  41. ncbi request reprint Inhibition of HIV replication by the plasminogen activator is dependent on vitronectin-mediated cell adhesion
    Chiara Elia
    DIBIT, AIDS Immunopathogenesis Unit, San Raffaele Scientific Institute, Via Olgettina, 58, 20132, Milan, Italy
    J Leukoc Biol 82:1212-20. 2007
    ..In conclusion, uPA inhibits HIV-1 replication in macrophages via up-regulation of cell adhesion to the substrate mediated by VN...
  42. doi request reprint Identification of TRIM22 single nucleotide polymorphisms associated with loss of inhibition of HIV-1 transcription and advanced HIV-1 disease
    Silvia Ghezzi
    aViral Pathogens and Biosafety Unit, Division of Immunology, Transplantation and Infectious Diseases bDepartment of Infectious Diseases cDivision of Genetics and Cell Biology, San Raffaele Scientific Institute dUniversity of Milan eGEMIB srl, Parma fAIDS Immunopathogenesis Unit, Division of Immunology, Transplantation and Infectious Diseases, San Raffaele Scientific Institute gUniversità Vita Salute San Raffaele, School of Medicine, Milan, Italy
    AIDS 27:2335-44. 2013
    ..We tested whether these variants affected the inhibitory effect of TRIM22 on HIV-1 replication and transcription and their potential association with HIV-1 disease...
  43. doi request reprint Risk of developing specific AIDS-defining illnesses in patients coinfected with HIV and hepatitis C virus with or without liver cirrhosis
    Antonella d'Arminio Monforte
    Clinic of Infectious and Tropical Diseases, Dept of Medicine, Surgery and Dentistry, San Paolo Hospital, University of Milan, via A Di Rudinì 8 20142, Milan, Italy
    Clin Infect Dis 49:612-22. 2009
    ..We evaluated the correlation between the occurrence of different AIDS-defining illnesses (ADIs) and chronic HCV infection or HCV-related liver cirrhosis in a large Italian cohort of human immunodeficiency virus (HIV)-infected subjects...
  44. ncbi request reprint Stavudine or indinavir-containing regimens are associated with an increased risk of diabetes mellitus in HIV-infected individuals
    Anna Maria Brambilla
    Infectious Diseases Clinic, Vita Salute University, San Raffaele Scientific Institute, Milan, Italy
    AIDS 17:1993-5. 2003
    ..Older men with HIV infection should be considered at higher risk of diabetes, and caution maybe warranted in the use of both indinavir and stavudine in these patients...
  45. ncbi request reprint The appealing story of HIV entry inhibitors : from discovery of biological mechanisms to drug development
    Antonella Castagna
    Clinic of Infectious Diseases, San Raffaele Scientific Institute, Milan, Italy
    Drugs 65:879-904. 2005
    ....